Home Alzheimer’s Disease Stereotactic Ablative Body Radiotherapy Improved Survival, Maintained Safety for Oligometastatic Cancers

Stereotactic Ablative Body Radiotherapy Improved Survival, Maintained Safety for Oligometastatic Cancers

The use of stereotactic ablative body radiotherapy (SABR) among patients with extracranial oligometastatic cancer was associated with higher overall survival (OS) and low toxicity rates, signaling the potential success for this treatment option moving forward, according to data published in The Lancet Oncology.

The data are supported by existing literature from a randomized phase 2 trial, providing even more high-level, real-world evidence in support of SABR for patients in this disease cohort. A randomized, phase 3 trial is currently underway to evaluate this treatment option further.

“The results show that patients with metachronous extracranial oligometastases treated with SABR in a real-world setting achieve high rates of 1-year and 2-year OS with low rates of severe (grade 3-4) toxicity,” wrote the investigators. “Our study provides real-world evidence characterising the use…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments